| October 11, 2006 |
| January 8, 2008 |
| April 2006 |
| November 2006 (final data collection date for primary outcome measure) |
| Change from baseline in total nasal symptom score during the peak period of the ragweed pollen season. [ Time Frame: Two years ] [ Designated as safety issue: No ] |
| Change from baseline in total nasal symptom score during the peak period of the ragweed pollen season. |
| Complete list of historical versions of study NCT00387738 on ClinicalTrials.gov Archive Site |
| |
| |
| |
| Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults |
| A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Dose-Regimen Study of the Efficacy and Safety of TOLAMBA™ in Ragweed-Allergic Rhinitis Adults |
The purpose of this study is to find out if a new investigational vaccine, TOLAMBA™, is safe and effective in reducing the symptoms of ragweed allergy. |
Ragweed allergy is the most common seasonal allergy in North America. Allergen immunotherapy is a therapeutic option for patients who have allergy symptoms that cannot be adequately controlled by avoidance of the allergen or medication. It may also be appropriate for those who cannot tolerate their medications due to side effects or have difficulties with medication compliance. This study compares the safety and efficacy of two different dosing regimens of TOLAMBA™ with placebo in reducing the symptoms of ragweed-allergic adults over two consecutive ragweed pollen seasons.
Comparison(s): Subject-rated allergy symptoms of subjects treated with TOLAMBA™ dose-intense regimen or TOLAMBA™ lower-dose regimen, compared with subjects treated with placebo. |
| Phase II |
| Interventional |
| Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Rhinitis, Allergic, Seasonal |
- Biological: Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
- Biological: Histamine base
|
- Experimental: TOLAMBA™ dose-intense regimen
- Experimental: TOLAMBA™ lower-dose regimen
|
| |
| |
| Terminated |
| 738 |
| June 2007 |
| November 2006 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- Has a history of ragweed allergic rhinitis (hayfever) during at least the last 2 consecutive seasons that has required treatment with antihistamines, decongestants and/or nasal steroids, but where symptom relief has been incomplete
- Is willing to stay in their ragweed area during the historical peak period of the local ragweed season, and willing to travel for no more than 2 weeks (cumulative time) outside of their ragweed area during the entire season
Exclusion Criteria:
- Has had any hospital admissions for asthma
- Has smoked within the past year, or has a ≥10-pack per year smoking history
- Has had any previous immunotherapy with ragweed pollen extract, or was in a previous clinical trial with TOLAMBA™
- Has used Xolair within the past 12 months
- Has a history of anaphylaxis
|
| Both |
| 18 Years to 55 Years |
| No |
| Contact information is only displayed when the study is recruiting subjects |
| United States |
| |
| NCT00387738 |
| Eduardo Martins, MD, DPhil / Vice President, Clinical Development, Dynavax Technologies Corporation |
| DV1-SAR-09 |
| Dynavax Technologies Corporation |
|
| Study Director: |
Eduardo Martins, MD, DPhil |
Dynavax Technologies Corporation |
|
|
| Dynavax Technologies Corporation |
| January 2008 |
